A woman who says her medical condition improved after she joined a clinical trial for an experimental drug cannot force the drug maker to keep providing it to her, a federal judge has ruled.
Northern District Judge Thomas McAvoy (See Profile) has rejected the remaining causes of action against Insmed Inc., a Richmond, Va.-based pharmaceutical company that developed the drug IPLEX for the treatment of Myotonic Muscular Dystrophy Type 1 (MMD1) but has now stopped production.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]